Status:
COMPLETED
A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants
Lead Sponsor:
Biogen
Conditions:
Healthy Volunteers
Eligibility:
MALE
21-45 years
Phase:
PHASE1
Brief Summary
The primary objective of the study is to explore the pharmacodynamic (PD) effects of BIIB104 on brain circuitry associated with emotional processing in healthy participants. The secondary objectives ...
Eligibility Criteria
Inclusion
- Key
- Have a body mass index (BMI) between 18 and 30 kilogram per meter square (kg/m\^2), inclusive.
- Right-handed as determined by the Edinburgh Handedness Inventory (score of \>40) \[Oldfield 1971\].
- Key
Exclusion
- Previous participation in this study or previous studies with BIIB104.
- Body weight \<55 kg.
- History of severe allergic or anaphylactic reactions, or systemic hypersensitivity reaction to BIIB104 or any allergic reactions that in the opinion of the Investigator are likely to be exacerbated by any component of the study treatment.
- NOTE: Other protocol defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
November 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 11 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04068532
Start Date
November 15 2019
End Date
November 11 2020
Last Update
March 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
London, United Kingdom, NW10 7EW